Publication:
Effects of Oleacein, a New Epinutraceutical Bioproduct from Extra Virgin Olive Oil, in LPS-Activated Murine Immune Cells.

dc.contributor.authorMuñoz-García, Rocío
dc.contributor.authorSánchez-Hidalgo, Marina
dc.contributor.authorMontoya, Tatiana
dc.contributor.authorAlcarranza, Manuel
dc.contributor.authorOrtega-Vidal, Juan
dc.contributor.authorAltarejos, Joaquín
dc.contributor.authorAlarcón-de-la-Lastra, Catalina
dc.date.accessioned2023-05-03T14:20:16Z
dc.date.available2023-05-03T14:20:16Z
dc.date.issued2022-10-28
dc.description.abstractThe present study was designed to evaluate the immunomodulatory effects of the secoiridoid from extra virgin olive oil, oleacein (OLA), deepening into the possible signaling pathways involved in LPS-activated murine peritoneal macrophages. Moreover, we have explored OLA-induced epigenetic changes in histone markers and related cytokine production in murine LPS-stimulated murine splenocytes. Murine cells were treated with OLA in the presence or absence of LPS (5 μg/mL) for 18 or 24 h. OLA modulated the oxidative stress and the inflammatory response produced by LPS stimulation in murine peritoneal macrophages, by the inhibition of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β, IFN-γ, IL-17 and IL-18) and ROS production and the expression of pro-inflammatory enzymes such as iNOS, COX-2 and m-PGES1. These protective effects could be due to the activation of the Nrf-2/HO-1 axis and the inhibition of JAK/STAT, ERK and P38 MAPKs and inflammasome canonical and non-canonical signaling pathways. Moreover, OLA modulated epigenetic modifications throughout histone methylation deacetylation (H3K18ac) and (H3K9me3 and H3K27me) in LPS-activated spleen cells. In conclusion, our data present OLA as an interesting anti-inflammatory and antioxidant natural compound that is able to regulate histone epigenetic markers. Nevertheless, additional in vivo studies are required to further investigate the beneficial effects of this EVOO secoiridoid, which might be a promising epinutraceutical bioproduct for the management of immune-related inflammatory diseases.
dc.identifier.doi10.3390/ph15111338
dc.identifier.issn1424-8247
dc.identifier.pmcPMC9699377
dc.identifier.pmid36355509
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9699377/pdf
dc.identifier.unpaywallURLhttps://www.mdpi.com/1424-8247/15/11/1338/pdf?version=1666963169
dc.identifier.urihttp://hdl.handle.net/10668/21536
dc.issue.number11
dc.journal.titlePharmaceuticals (Basel, Switzerland)
dc.journal.titleabbreviationPharmaceuticals (Basel)
dc.language.isoen
dc.organizationHospital Universitario Virgen del Rocío
dc.organizationInstituto de Biomedicina de Sevilla-IBIS
dc.pubmedtypeJournal Article
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectepigenetic
dc.subjecthistone
dc.subjectimmunity
dc.subjectinflammation
dc.subjectmacrophages
dc.subjectoleacein
dc.subjectolive oil
dc.subjectspleen cells
dc.titleEffects of Oleacein, a New Epinutraceutical Bioproduct from Extra Virgin Olive Oil, in LPS-Activated Murine Immune Cells.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number15
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC9699377.pdf
Size:
3.37 MB
Format:
Adobe Portable Document Format